FierceBiotech4h
Gilead’s O’Day relishes Berger reunion as cancer specialist agrees to join from Sanofi
Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...
Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...
The Pharma Letter1h
Gilead Sciences names new CMO
US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief ...
FiercePharma1d
With Biktarvy patent cliff ahead, Gilead lays out a plan to keep the HIV crown with 7 launches through 2033
Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...
STAT1d
Gilead to test once-a-year HIV prevention shot
Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.
Business Insider6h
Gilead Sciences Says Seladelpar Gets Positive CHMP Opinion For Primary Biliary Cholangitis
(RTTNews) - Gilead Sciences, Inc. (GILD) announced Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion ...
Hosted on MSN22h
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...
FY2025 EPS Forecast for Gilead Sciences Increased by Analyst
Equities research analysts at Zacks Research raised their FY2025 earnings per share (EPS) estimates for Gilead Sciences in a ...
Looking For Yields: IDACORP, Gilead Sciences and Fifth Third Bancorp Are Consistent Moneymakers
Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.